• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Review of Diabetic Studies : RDS >New Therapeutic Approaches in Diabetic Retinopathy
【24h】

New Therapeutic Approaches in Diabetic Retinopathy

机译：糖尿病性视网膜病变的新治疗方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.
机译：糖尿病性视网膜病是糖尿病的常见微血管并发症。它影响了美国40岁以上成年人的很大一部分。这种情况是视力丧失的主要原因。随着研究各种新疗法和药物输送方法的发展，人们对扩大当前治疗的作用给予了极大的关注。在糖尿病性黄斑水肿（DME）的治疗中，玻璃体内药物疗法，尤其是抗血管内皮生长因子（anti-VEGF）剂，已经普及。目前，抗VEGF药物经常被用作涉及中心的DME的一线药物，最近的数据表明，在这些药物中，aflibercept可使基线视力较差的患者获得更好的视觉效果。尽管光凝仍然是增生性糖尿病视网膜病变（PDR）的标准治疗方法，但最近FDA批准兰尼单抗和aflibercept在与DME相关的糖尿病性视网膜病变的治疗中可能也暗示着药物治疗PDR的潜力。目前正在评估包括糖尿病小分子干扰RNA，趋化因子，激肽释放酶激肽抑制剂和各种抗血管生成剂在内的新疗法，以治疗糖尿病性视网膜病变和DME。除了这些策略之外，诸如持续释放植入物和可再填充储库植入物之类的新型药物输送方法正在积极评估中，或者最近已获得FDA批准。这篇综述提供了在糖尿病性视网膜病治疗中新进展的更新。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号